About scPharmaceuticals
scPharmaceuticals is a company based in Lexington (United States) founded in 2013 was acquired by MannKind Corp in August 2025. scPharmaceuticals has raised $78.75 million across 4 funding rounds from investors including MannKind Corp, Sun Pharma and Orbimed. The company has 164 employees as of December 31, 2024. scPharmaceuticals offers products and services including FUROSCIX. scPharmaceuticals operates in a competitive market with competitors including Valeritas, Crossject, Incline Therapeutics, VeraDermics and CeQur, among others.
- Headquarter Lexington, United States
- Employees 164 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Scpharmaceuticals Inc.
-
Annual Revenue
$36.33 M (USD)167.28as on Dec 31, 2024
-
Net Profit
-$85.15 M (USD)-55.35as on Dec 31, 2024
-
EBITDA
-$64.63 M (USD)-18as on Dec 31, 2024
-
Total Equity Funding
$78.75 M (USD)
in 4 rounds
-
Latest Funding Round
$46.96 M (USD), Series B
Jan 06, 2017
-
Investors
MannKind Corp
& 5 more
-
Employee Count
164
as on Dec 31, 2024
-
Acquired by
MannKind Corp
(Aug 25, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of scPharmaceuticals
scPharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol SCPH in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of scPharmaceuticals
scPharmaceuticals offers a comprehensive portfolio of products and services, including FUROSCIX.
Treats heart failure and kidney disease via subcutaneous delivery.
Funding Insights of scPharmaceuticals
scPharmaceuticals has successfully raised a total of $78.75M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $46.96 million completed in January 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in scPharmaceuticals
scPharmaceuticals has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include MannKind Corp, Sun Pharma and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
Venture capital fund backed incubator focused on the healthcare startups
|
Locked | Locked | Locked | |
|
Life science companies are funded through venture capital investments.
|
Locked | Locked | Locked |
Investor details for scPharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by scPharmaceuticals
Investment portfolio details for scPharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - scPharmaceuticals
Detailed financials for scPharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Scpharmaceuticals Comparisons
Peer comparison for scPharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of scPharmaceuticals
scPharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Valeritas, Crossject, Incline Therapeutics, VeraDermics and CeQur, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Wearable insulin patch pumps are developed for transdermal delivery.
|
|
| Locked | Locked | Locked |
Needle-free self-injectable drugs
|
|
| Locked | Locked | Locked |
Hospital-focused specialty pharmaceuticals are developed for acute pain management.
|
|
| Locked | Locked | Locked |
Drug-delivery platforms for pediatric wart treatments are developed.
|
|
| Locked | Locked | Locked |
Wearable insulin delivery patches are developed for mealtime dosing.
|
Detailed competitors of scPharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Scpharmaceuticals
Complete news archive for scPharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about scPharmaceuticals
scPharmaceuticals was founded in 2013 and raised its 1st funding round 1 year after it was founded.
scPharmaceuticals is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.
scPharmaceuticals is a funded company, having raised a total of $78.75M across 4 funding rounds to date.
As of Dec 31, 2024, the latest employee count at scPharmaceuticals is 164.
Annual revenue of scPharmaceuticals is $36.33M as on Dec 31, 2024.
Provider of a device for subcutaneous drug delivery for the treatment of bacterial infections and heart failure. The company has developed a device called sc2Wear Pump that facilitates subcutaneous drug administration over durations, rates, and volumes that can be tailored to specific drugs. The pipeline includes Furosemide for heart failure, Ceftriaxone, and Ertapenem to treat bacterial infections.
scPharmaceuticals offers FUROSCIX.
Yes, scPharmaceuticals is publicly traded on NASDAQ under the ticker symbol SCPH.
scPharmaceuticals has 6 investors. Key investors include MannKind Corp, Sun Pharma, Orbimed, 5AM Ventures, and Lundbeck Foundation.
The ticker symbol of scPharmaceuticals is SCPH on NASDAQ.